Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WEST LAFAYETTE, Ind., May 30, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's investigational cancer candidate, vintafolide (EC145) and its non-invasive, companion diagnostic imaging agent, etarfolatide (EC20) will be featured at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, May 31 to June 4.
Help employers find you! Check out all the jobs and post your resume.
WEST LAFAYETTE, Ind., May 30, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's investigational cancer candidate, vintafolide (EC145) and its non-invasive, companion diagnostic imaging agent, etarfolatide (EC20) will be featured at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, May 31 to June 4.
Help employers find you! Check out all the jobs and post your resume.
